Buying the radiopharmaceutical business of Fujifilm Toyama Chemical and consolidating PDR Pharma (2021)

The weight of a second pillar

To read this acquisition only as a highly profitable venture comfortably buying itself a second pillar is to make the state of the business too simple. PeptiDream’s founding trade — joint research and technology licensing — carried very high margins, as an operating margin of 59% shows, but it rested on partnerships and contract work with others and lacked any product the company manufactured and sold itself. That it took in radiopharmaceuticals together with their manufacturing and marketing base, at a time when announcing new partnerships had stopped moving the share price, suggests an intent to break out of dependence on a single platform.

Even so, gaining a second pillar did not in itself bring stability. Just before completion the consideration was cut from $277.8M (¥31bn) to $168.2M (¥22bn) when sales rights were returned, and the radiopharmaceutical business that widened the consolidated scale at a stroke brought with it the weight of goodwill and intangible-asset amortisation. That revenue shrank and operating results turned to a loss in the year to December 2025 shows that a decision to rebuild the business on two pillars brings scale and volatility of earnings bundled together. How to mesh a manufacturing-and-marketing business of an entirely different nature with the high profitability of the founding trade is the problem left over once the acquisition was done.